drugset
drugset / Trial / NCT07703956

Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

NCT07703956 ↗

Phase 2 Not yet recruiting 500 enrolled Vigonvita Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase.

Timeline

Start
2026-07-31
Primary completion
2027-10-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 20 mg Oral
Subject VV119 Unknown 2 mg Oral
Subject VV119 Unknown 4 mg Oral
Subject VV119 Unknown 6 mg Oral

Indications

schizophrenia